Novartis (NVS) has announced that it will acquire Tourmaline Bio, Inc. (TRML), a New York-based, publicly traded clinical-stage biopharmaceutical company, for $1.4 billion. The acquisition will add ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results